ArticleFrontiers in cellular and infection microbiology2021
Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.Antimicrobial resistance and infection control · 2025Pooled it
- Optimal treatment of Imipenem and meropenem against bloodstream infections caused by the Citrobacter spp.BMC infectious diseases · 2025Article
- Assessment of broth disk elution method for aztreonam in combination with ceftazidime/avibactam againstMicrobiology spectrum · 2024Article
- Dynamic cytokine profiles of bloodstream infection caused by Klebsiella pneumoniae in China.Annals of clinical microbiology and antimicrobials · 2024Article
- Metabolomics unveil key pathways underlying the synergistic activities of aztreonam and avibactam against multidrug-resistant Escherichia coli.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- In vitro activity of antibiotics potentially effective against difficult-to-treat strains of Gram-negative rods: retrospective study.Scientific reports · 2024Article
- Ceftazidime-Decorated Gold Nanoparticles: a Promising Strategy against Clinical Ceftazidime-Avibactam-ResistantAntimicrobial agents and chemotherapy · 2023Article
- Novel Antimicrobial Agents for Gram-Negative Pathogens.Antibiotics (Basel, Switzerland) · 2023Review
- A Simple Disk Stacking Plus Micro-Elution Method for Rapid Detection of the Synergistic Effect of Aztreonam and Ceftazidime/Avibactam Against Metallo-β-Lactamase Producing Enterobacterales.Infection and drug resistance · 2023Article
- Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR)Frontiers in cellular and infection microbiology · 2023Article
- Aztreonam-avibactam synergy, a validation and comparison of diagnostic tools.Frontiers in microbiology · 2023Article
- Whole Genome Sequencing and Molecular Analysis of Carbapenemase-ProducingMicroorganisms · 2022Article
- Molecular Mechanisms Mediating Ceftazidime/Avibactam Resistance Amongst Carbapenem-ResistantInfection and drug resistance · 2022Article
- Epidemiology and Genomic Characteristics of Bloodstream Infection Caused by Carbapenem-ResistantFrontiers in cellular and infection microbiology · 2022Article
- Antibacterial Activity and Optimal Treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections Caused by Carbapenem-ResistantFrontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The aim of this work was to investigate the activity of ceftazidime-avibactam (CZA) and aztreonam-avibactam (AZA) against bloodstream infections caused by carbapenem-resistant organisms (CROs). Methods: Non-duplicate CROs, including 56 carbapenem-resistant Results: The resistance rate of polymyxin B against CROs was less than 5%. Only one CR-Kpn was resistant to tigecycline. The resistance rates of CZA against CR-Eco, CR-Kpn, and CR-Pae were 75.0%, 12.6%, and 18.5%, respectively. The MIC Conclusions: The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.